[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338044-105":59,"doc-detail-338044-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","erdafitinib-in-asian-patients-with-advanced-solid-tumors-an-open-label-single-arm-phase-iia-trial","Erdafitinib in Asian patients with advanced solid tumors - an open-label, single-arm, phase IIa trial","","Erdafitinib efficacy and safety were evaluated in Asian patients with FGFR-altered advanced solid tumors, focusing on advanced cholangiocarcinoma, non-small cell lung cancer (NSCLC), and esophageal cancer. In this multicenter, open-label, single-arm phase IIa study, eligible patients received oral erdafitinib 8 mg once daily with option for up-titration to 9 mg, with a protocol-amendment exception for four NSCLC patients. Primary endpoint was investigator-assessed objective response rate by RECIST v1.1. Thirty-five patients were enrolled, with meaningful responses mainly in cholangiocarcinoma and tolerable safety without new signals.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/erdafitinib-in-asian-patients-with-advanced-solid-tumors-an-open-label-single-arm-phase-iia-trial/338044/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/erdafitinib-in-asian-patients-with-advanced-solid-tumors-an-open-label-single-arm-phase-iia-trial/338044.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary endpoint of the phase IIa trial?","Question",{"text":112,"@type":113},"The primary endpoint was investigator-assessed objective response rate according to RECIST v1.1.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which tumor types were included in the study and how did responses differ?",{"text":117,"@type":113},"Patients had FGFR-altered advanced cholangiocarcinoma, NSCLC, or esophageal cancer. Objective responses were observed for cholangiocarcinoma, while no objective response was achieved in RET/FGFR-altered NSCLC; the single esophageal-cancer patient achieved partial response.",{"name":119,"@type":110,"acceptedAnswer":120},"How was erdafitinib dosed during the trial and what was the safety finding?",{"text":121,"@type":113},"Patients received erdafitinib 8 mg once daily, with an option for pharmacodynamically guided up-titration to 9 mg on a 28-day cycle (with an exception dosing schedule for four NSCLC patients). All patients experienced treatment-emergent adverse events, and grade ≥3 events occurred in 22 (62.9%) patients, with hyperphosphatemia the most frequently reported adverse event.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338044,1790803404,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Park etal. BMC Cancer (2024) 24:1006 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-12584-0](https://doi.org/10.1186/s12885-024-12584-0)  \nRESEARCH Open Access  \nErdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial  \nJoon Oh Park 1*, Yin-Hsun Feng2, Wu-Chou Su3, Do-Youn Oh4, Bhumsuk Keam5, Lin Shen6, Sang-We Kim7, Xiufeng Liu8, Huimin Liao9, Min Qing9, Chong Zhang9, Jiaqi Qian9, Xiaodan Tang9, Peng Li9, SpyrosTriantos 10 and Hussein Sweiti 10  \nAbstract  \nBackground FGFR genomic aberrations occur in approximately 5–10% of human cancers. Erdafitinib has previously demonstrated efficacy and safety in FGFR-altered advanced solid tumors, such as gliomas, thoracic, gastrointestinal, gynecological, and other rare cancers. However, its efficacy and safety in Asian patients remain largely unknown. We conducted a multicenter, open-label, single-arm phase IIa study of erdafitinib to evaluate its efficacy in Asian patients with FGFR-altered advanced cholangiocarcinoma, non-small cell lung cancer (NSCLC), and esophageal cancer. Methods Patients with pathologically/cytologically confirmed, advanced, or refractory tumors who met molecular and study eligibility criteria received oral erdafitinib 8 mg once daily with an option for pharmacodynamically guided up-titration to 9 mg on a 28-day cycle, except for four NSCLC patients who received erdafitinib 10 mg (7 days on/7 days off ) as they were recruited before the protocol amendment. The primary endpoint was investigator-assessed objective response rate per RECIST v1 .1. Secondary endpoints included progression-free survival, duration of response, disease control rate, overall survival, safety, and pharmacokinetics.  \nResults Thirty-five patients (cholangiocarcinoma: 22; NSCLC: 12; esophageal cancer: 1) were enrolled. At data cutoff (November 19, 2021), the objective response rate for patients with cholangiocarcinoma was 40 . 9%(95% CI, 20.7–63. 6); the median progression-free survival was 5.6 months (95% CI, 3 .6–12. 7) and median overall survival was  \n40.2 months (95% CI, 12.4–not estimable) . No patient with RET/FGFR-altered NSCLC achieved objective response and the disease control rate was 25 . 0%(95% CI, 5 .5–57. 2%), with three patients with stable disease. The single patient with esophageal cancer achieved partial response. All patients experienced treatment-emergent adverse events, and grade ≥ 3 treatment-emergent adverse events were reported in 22 (62 . 9%) patients. Hyperphosphatemia was the most frequently reported treatment-emergent adverse event (all-grade, 85 . 7%) .  \nConclusions Erdafitinib demonstrated efficacy in a population of Asian patients in selected advanced solid tumors, particularly in those with advanced FGFR-altered cholangiocarcinoma. Treatment was tolerable with no new safety signals.  \n*Correspondence: Joon Oh Park [oncopark@skku.edu](oncopark@skku.edu)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero","cbCaiktnrcVoJ4Qa","https://ap.wps.com/l/cbCaiktnrcVoJ4Qa","pdf",2945599,13,"English","# Abstract\n# Background\n# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What was the primary endpoint of the phase IIa trial?\",\"answer\":\"The primary endpoint was investigator-assessed objective response rate according to RECIST v1.1.\"},{\"question\":\"Which tumor types were included in the study and how did responses differ?\",\"answer\":\"Patients had FGFR-altered advanced cholangiocarcinoma, NSCLC, or esophageal cancer. Objective responses were observed for cholangiocarcinoma, while no objective response was achieved in RET/FGFR-altered NSCLC; the single esophageal-cancer patient achieved partial response.\"},{\"question\":\"How was erdafitinib dosed during the trial and what was the safety finding?\",\"answer\":\"Patients received erdafitinib 8 mg once daily, with an option for pharmacodynamically guided up-titration to 9 mg on a 28-day cycle (with an exception dosing schedule for four NSCLC patients). All patients experienced treatment-emergent adverse events, and grade ≥3 events occurred in 22 (62.9%) patients, with hyperphosphatemia the most frequently reported adverse event.\"}]","Erdafitinib in Asian patients with advanced solid tumors - an open-label, single-arm, phase IIa trial | PDF",1790021703,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63fc2cd40b71a600adf1c9873e9629af.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c726a344e2fc98a25303a5225f0f726.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46a55edbc961f47223bf33076cb12a2f.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b83bd86878e4429c0293cbf82255238b.webp",980,1306]